Aclaris Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACRS research report →
Companywww.aclaristx.com
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research.
- CEO
- Neal S. Walker
- IPO
- 2015
- Employees
- 61
- HQ
- Wayne, PA, US
Price Chart
Valuation
- Market Cap
- $546.30M
- P/E
- -8.38
- P/S
- 65.29
- P/B
- 4.06
- EV/EBITDA
- -7.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.34%
- Op Margin
- -961.91%
- Net Margin
- -832.58%
- ROE
- -55.89%
- ROIC
- -46.81%
Growth & Income
- Revenue
- $7.83M · -58.19%
- Net Income
- $-64,923,000 · 50.84%
- EPS
- $-0.53 · 69.01%
- Op Income
- $-76,375,000
- FCF YoY
- -133.28%
Performance & Tape
- 52W High
- $5.15
- 52W Low
- $1.22
- 50D MA
- $4.12
- 200D MA
- $2.96
- Beta
- 0.78
- Avg Volume
- 1.89M
Get TickerSpark's AI analysis on ACRS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Hall Jesse Wayne | other | 36,375 |
| May 1, 26 | Hall Jesse Wayne | other | 36,375 |
| May 1, 26 | Hall Jesse Wayne | other | 9,330 |
| Apr 23, 26 | Leonard Braden Michael | sell | 300,000 |
| Mar 1, 26 | Balthaser Kevin | other | 2,375 |
| Mar 1, 26 | Balthaser Kevin | other | 677 |
| Mar 1, 26 | Balthaser Kevin | other | 2,375 |
| Feb 2, 26 | Walker Neal | other | 961,700 |
| Feb 2, 26 | Walker Neal | other | 274,800 |
| Feb 2, 26 | Davis Hugh M. | other | 336,300 |
Our ACRS Coverage
We haven't published any research on ACRS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACRS Report →